Make a name for yourself, like Andrea.
You’re 7 minutes away from a page that shows who you are and what you do.
Andrea de Bartolomeis
Andrea de Bartolomeis
Andrea de Bartolomeis M.D., Ph.D. is Associate Professor of Psychiatry, director of the Section of Psychiatry and Treatment Resistant Psychosis program at Department of Neuroscience, University School of Medicine of Napoli Federico II,
He is also the Director of the Residency program in Psychiatry
Andrea de Bartolomeis received his medical degree and his residency training in psychiatry at the University of Naples Federico II, Italy.
He completed his postdoctoral training as recipient of Fogarty Fellowship in psychopharmacology and molecular pathophysiology of schizophrenia with NIMH in Bethesda MD (USA) first at Clinical Neuroscience Branch (1989-1992) and then at Experimental Therapeutics Branch (1993-1995) where he contributed to develop a novel method for quantitation of synaptic dopamine in vivo in primates, using PET and microdialysis simultaneously. This method was instrumental for the first demonstration in vivo by PET and 11C-raclopride of enhanced release of dopamine after amphetamine challenge in striatum of schizophrenics patients compared to normal controls.
He has been Visiting scientist at Neuroendocrinology Branch of NIMH, Bethesda, MD, USA, and Guest scientists at NIMH ETB and Anxiety Mood Disorder Program in several occasion from 1995 to 2000, for collaborating project
In 1998 he received from the University of Naples a Ph.D. degree in Methodology of Communication Science.
In 2001 he became chief of the Laboratory of Molecular and Translational Psychiatry.
The research interest of Andrea de Bartolomeis includes: the molecular
pathophysiology of psychosis, CNS gene expression modulation by psychotropic
drugs, and augmentation strategy in psychosis pharmacotherapy.
He has been principal investigator or co-investigator on several research and training grants as well on clinical trials from public and drug company sources.
He is member of the American Society for Neuroscience, International Society for Schizophrenia Research, New York Academy of Sciences, Italian Society of Neuroscience, Italian Society of Psychopathology, European Collegium of Neuropsychopharmacology.
He has been elected in the board of directors of the Italian Society for Neuroscience for the years 2012-2015.
He is member of board of directors of the Italian Chapter of International Bipolar Disorders Society
He has authored articles, book chapters, and published abstracts on molecular mechanisms of antipsychotics as well as on schizophrenia pathophysiology and molecular ima